Policy Developments - The Ministry of Commerce and nine other departments issued an opinion to promote the high-quality development of the pharmaceutical retail industry, proposing 18 specific measures focused on improving pharmaceutical services and emergency supply guarantees [1] - The opinion emphasizes the development of smart regulation, including accurate collection and verification of drug traceability codes and uploading to a national medical insurance information platform [1] - A dynamic regulatory model based on risk levels and credit evaluations will be implemented, optimizing inspection frequencies for low-risk enterprises and exploring non-on-site supervision methods like AI video inspections [1] Drug Approval - Yuandong Bio's subsidiary Shod Pharmaceutical received a drug registration certificate for chloral hydrate syrup, aimed at sedation and hypnosis for children, marking the company's first approved Class 2 modified new drug [2] - West Point Pharmaceutical announced the approval of glucosamine sulfate capsules for primary or secondary osteoarthritis, enhancing its product line but facing sales uncertainties due to industry policies and procurement factors [3] Capital Market - OpenEvidence, a medical AI startup, completed a $250 million Series D financing round, achieving a valuation of $12 billion, with total financing nearing $700 million [4] - West Point Pharmaceutical plans to repurchase shares worth between 25 million and 50 million RMB, with a maximum repurchase price of 42.00 RMB per share, representing 0.78% to 1.56% of its total A-share capital [5] Industry Developments - Baichuan Intelligent launched the evidence-enhanced medical model M3 Plus, reducing hallucination rates to 2.6%, the lowest globally, and introduced the "evidence anchoring" technology to link generated medical conclusions to original research [6][7] - Sinovac's inactivated hepatitis A vaccine has secured a two-year exclusive bid in Oman, with over 130 million doses supplied globally, making it one of the most widely used hepatitis A vaccines [8] Public Opinion Alerts - Yiju Medical announced the resignation of non-executive director Dr. Zhou Yi, effective January 22, 2026, to focus on other business commitments [9]

水合氯醛作为临床应用成熟的镇静催眠药物，其安全性与有效性已得到广泛验证，被中华医学会麻醉学 分会、美国急诊医师学院等国内外众多权威学术机构推荐为儿童镇静催眠常用药物或一线用药。国家药 监局官网显示，国内现有3款水合氯醛口服制剂获得批准，为特丰制药的水合氯醛/糖浆组合包装，以及 成都倍特得诺药业、海南鹏康药业的水合氯醛糖浆。 公司全资子公司硕德药业的水合氯醛糖浆是公司首款获得批准的2类改良型新药。该药品的获批，标志 着公司该产品符合药品注册的有关要求，进一步丰富了公司麻醉镇痛领域产品管线，对公司经营发展具 有一定的积极作用。 格隆汇1月22日丨苑东生物(688513.SH)公布，公司全资子公司成都硕德药业有限公司于近日收到国家药 监局核准签发的《药品注册证书》。药品名称：水合氯醛糖浆，药品注册标准编号：YBH26472025。 水合氯醛糖浆活性成份为水合氯醛，是一款针对儿科临床用药痛点设计的专用糖浆剂型，适应症为儿童 检查、操作前的镇静、催眠，属于《国家基本医疗保险、工伤保险和生育保险药品目录（2025年）》乙 类品种。与已上市的水合氯醛/糖浆组合包装相比，本品无需稀释即可直接给药，能精准调控给药剂 量，且专为 ...

Core Viewpoint - The approval of the drug "Hydrated Chloral Syrup" by the National Medical Products Administration marks a significant advancement for the company in the pediatric clinical medication sector, addressing specific needs for sedation and hypnosis in children [1][2] Group 1: Product Details - The active ingredient of Hydrated Chloral Syrup is hydrated chloral, designed specifically for pediatric use, with indications for sedation and hypnosis before examinations and procedures [1] - This product is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - Unlike existing hydrated chloral/syrup combination products, this syrup does not require dilution for administration, allowing for precise dosage control and improved palatability for children [1] Group 2: Market Context - Hydrated chloral is a well-established sedative and hypnotic drug, with its safety and efficacy widely validated and recommended by various authoritative medical institutions [1] - Currently, there are three approved oral formulations of hydrated chloral in China, including those from other pharmaceutical companies [1] Group 3: Company Impact - The approval of Hydrated Chloral Syrup represents the company's first approved Category II modified new drug, enhancing its product pipeline in the anesthesia and analgesia field [2] - This development is expected to have a positive impact on the company's operational growth [2]